ReviewBritish journal of haematology2008
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
Review in British journal of haematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma.Scientific reports · 2021Article
- Therapeutic vaccines for aggressive B-cell lymphoma.Leukemia & lymphoma · 2020Article
- New developments in immunotherapy for lymphoma.Cancer biology & medicine · 2018Article
- Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018Article
- Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.BioMed research international · 2015Article
- Lymphoma Immunotherapy: Current Status.Frontiers in immunology · 2015Review
- Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.International journal of cancer · 2014Article
- Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice.Journal of translational medicine · 2014Article
- Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Structural basis for the recognition in an idiotype-anti-idiotype antibody complex related to celiac disease.PloS one · 2014Article
- Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.American journal of blood research · 2014Review
- Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.Human vaccines & immunotherapeutics · 2013Review
- Article
- Immunotherapy for B-cell lymphoma: current status and prospective advances.Frontiers in immunology · 2012Article
- Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.World journal of clinical oncology · 2011Article
- Vaccination strategies in follicular lymphoma.Current hematologic malignancy reports · 2009Review
- Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.Nature reviews. Cancer · 2009Review
- HLA class I-restrictedOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Therapeutic vaccines for B-cell non-Hodgkin lymphoma (NHL) using the clonal tumour immunoglobulin idiotype (Id) have been under development for more than three decades. A major obstacle for rapid progress in the field has been that the Id vaccine is patient-specific and required the generation of a custom-made product. The manufacturing issues were recently overcome by advances in hybridoma and recombinant DNA technology which facilitated the completion of several phase I and II clinical trials. The strong immunogenicity and apparent clinical benefit observed on the early phase studies led to the initiation of three randomized phase III clinical trials that are also nearing completion. This review will focus on the development of Id vaccines before and after the introduction of rituximab for the treatment of B-cell NHL and also discuss potential strategies to enhance the efficacy of active immunotherapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.